ABSTRACT
The value of immunotherapy (IT) in allergic rhinitis is debated. The results of a retrospective study of 67 patients treated with IT from 1985 to the end of 1995 are reported. Patients were classified as cured, improved, or not improved. Variables such as age, number and type of allergens, improvement, release, duration of evolution, and initial and final IgE levels were analyzed. Response to IT was favorable in 81.1% of cases. Improvement and cure were age-dependent, with the cure rate being significantly higher in patients over 30.
Subject(s)
Desensitization, Immunologic , Rhinitis, Allergic, Perennial/therapy , Rhinitis, Allergic, Seasonal/therapy , Adolescent , Adult , Age Factors , Aged , Allergens/immunology , Allergens/therapeutic use , Child , Evaluation Studies as Topic , Female , Humans , Immunoglobulin E/blood , Male , Middle Aged , Retrospective Studies , Rhinitis, Allergic, Perennial/epidemiology , Rhinitis, Allergic, Perennial/immunology , Rhinitis, Allergic, Seasonal/epidemiology , Rhinitis, Allergic, Seasonal/immunology , Seasons , Spain/epidemiology , Treatment OutcomeABSTRACT
Peripheral facial paralysis is a common mononeuropathy in adults. It is less frequent in children, but is very upsetting for parents when it occurs. Its causes in children are similar to those found in adults, the most common being idiopathic. However, secondary facial paralysis is the most frequent cause in children. The results of a 4-year follow-up of 29 cases of peripheral facial paralysis in 26 children age 14 and under are reported. The causes, evolution, treatment, recuperation, care, and rate of admission are reviewed. Results are compared to those found in the follow-up of 196 adult cases of peripheral facial paralysis made by the authors.
